Ethyreal is a private clinical-stage biotechnology company developing antibody-based therapies for autoimmune endocrine disorders, with a focus on Graves' disease and the related thyroid eye disease (TED). Its lead candidate selectively targets the IGF-1 receptor pathway in orbital fibroblasts.
Company Info
Funding & Investor Relations
None publicly disclosed; clinical-stage autoimmune biotech.
Upcoming Milestones & Key Dates
Phase 2 ETH-101 interim data in thyroid eye disease
Phase 1 ETH-201 first-in-human readout in Graves' disease
Clinical Development Pipeline
Recent News
Ethyreal Bio emerged from stealth with $101 million in financing to advance ETHY-001, a potential best-in-class anti-TSHR antibody for thyroid eye disease and Graves' disease.
Ethyreal Therapeutics closed a $101M financing to advance a dual-acting antibody aimed at both Graves' disease and thyroid eye disease, two autoimmune indications with overlapping biology but few targeted therapies.
Leadership Team
Careers & Job Openings